By Julia Pian, Senior Associate at Atlas Venture, as part of the From The Trenches features of LifeSciVC
As Jonathan Larson beautifully explores in “Seasons of Love” from Rent, it’s almost impossible to find the right variables to capture life experiences. Yet frequently in the diligence process, we are trying to understand whether indications like ADA-SCID or CGD have “enough” treatable patients or indications like Heme B or CF have “enough” remaining unmet need given existing therapies to garner venture investment in the early R&D process.
In this post, we will walk through how one integrates key aspects of the patient…